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Protein misfolding disorders and macroautophagy
Fiona M Menziesa, Kevin Moreaua and David C RubinszteinA large group of diseases, termed protein misfolding disorders,
share the common feature of the accumulation of misfolded
proteins. The possibility of a common mechanism underlying
either the pathogenesis or therapy for these diseases is
appealing. Thus, there is great interest in the role of protein
degradation via autophagy in such conditionswhere the protein
is found in the cytoplasm. Here we review the growing evidence
supporting a role for autophagic dysregulation as a contributing
factor to protein accumulation and cellular toxicity in certain
proteinmisfolding disorders and discuss the available evidence
that upregulation of autophagy may be a valuable therapeutic
strategy.
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Introduction
Protein misfolding disorders or proteinopathies appear, at
the clinical level, to be a diverse group of disorders encom-
passing many diseases, from late-onset neurodegenerative
disorders through to forms of heart failure. These con-
ditions are unified by the common feature of accumulation
of misfolded proteins. The specific protein, cell type and
cellular localisation of these accumulations vary between
the diseases. For example, Parkinson’s disease is charac-
terised by the presence of cytoplasmic aggregates of a-
synuclein, whereas in the polyglutamine expansion dis-
orders, aggregates are seen predominantly within the
nucleus in spinocerebellar ataxia type1, or in the cytoplasm
in adult-onset Huntington’s disease. In Alzheimer’s dis-
ease (AD), both intracellular tau aggregates and extracellu-
lar amyloid-b (Ab) aggregates are seen.
Macroautophagy, which we will refer to as autophagy, is
an intracellular process in which cytoplasmic materials
are engulfed by double membrane structures, which
Open access under CC BY license. Current Opinion in Cell Biology 2011, 23:190–197form autophagosomes. The autophagosomes first fuse
with endosomes to form hybrid organelles called amphi-
somes that later fuse with lysosomes, where the
entrapped cytosolic contents are degraded. The mech-
anisms of autophagy are described elsewhere in this
review issue. The process of macroautophagy has been
proposed to be important in protein misfolding dis-
orders, both as a contributing factor, through inhibition
of the process, and a potential therapeutic strategy,
through its upregulation (Figure 1). Here we will discuss
the evidence for both these possibilities, concentrating
on the neurodegenerative proteinopathies in which mis-
folded protein accumulation is seen in the central ner-
vous system.
Inhibition of macroautophagy as a
contributing factor in proteinopathies
Macroautophagy is induced following various stimuli, the
most studied of which is starvation, where upregulation of
autophagy acts to provide vital cellular nutrients. In the
brain there was thought to be little induction of autop-
hagy following starvation [1], although this view has been
challenged by a recent study suggesting profound autop-
hagy upregulation after starvation [2]. Clarification of this
issue may require refinement of methods to assess autop-
hagic flux in the brain. In post-mitotic cells, such as
neurons, turnover of proteins and organelles is particu-
larly important for cellular quality control, and basal (or
constitutive) autophagy appears to be vital to maintain
this. Complete knockout of the essential autophagy genes
Atg5 or Atg7 in mice causes lethality soon after birth [3,4].
However, selective knockout of these genes in neuronal
cells results in a phenotype closely resembling those seen
in neurodegenerative diseases, as well as protein aggrega-
tion without the expression of a disease-causing protein
[5,6].
There is also accumulating evidence for the fact that
aggregating, misfolded proteins may have an impact on
autophagic function, suggesting that this could be a
secondary pathological mechanism in many diseases.
This aspect will be discussed below.
Huntington’s disease
Huntington’s disease (HD) is a hereditary neurodegen-
erative disease resulting from an expansion of the poly-
glutamine region of the ubiquitously expressed protein
huntingtin (htt) [7]. This mutant protein accumulates
inside cells, forming toxic oligomeric species and aggre-
gates. Immunohistochemistry and electron microscopy
approaches, either in HD patients or experimental
models, have suggested alterations in the autophagicwww.sciencedirect.com
Protein misfolding disorders and macroautophagy Menzies, Moreau and Rubinsztein 191
Figure 1
Aggregate
Prone
Protein
AutophagymTOR activity
Protein trafficking
Cytotoxicity & Neurodegeneration
Cytoprotection
+-
Rapamycin
SMERs
Lithium
Trehalose
Rilmenidine
Cl
ea
ra
n
ceGa
in 
of 
fun
ctio
n
Current Opinion in Cell Biology
A model for autophagy regulation in proteinopathies. An interconnected system exists in which autophagy is able to control the levels of
intracytoplasmic aggregate-prone proteins (green arrow). However, these proteins are also able to control levels of autophagy (blue arrows).
Additionally levels of autophagy are also able to be regulated using drugs (red arrow). The balance between these factors will alter cell survival.pathway. The earliest evidence comes from observations
of increased numbers of autophagic vacuoles across a
range of HD models and in patients [8–13]. While it is
not clear if this is due to enhanced autophagosome
formation or decreased clearance of the vesicles, mTOR
is inactivated by cells with mutant huntingtin inclusions,
as it is sequestered into aggregates, and this would be
compatible with autophagy upregulation [14].
More recently, it has been reported that the autophagic
turnover of cytoplasmic components is partially impaired
in cells expressing mutant huntingtin (Table 1) [15].
While autophagosomes are able to form and fuse with
lysosomes, the authors report that expression of mutant
huntingtin results in inefficient cargo loading, although
mutant huntingtin is efficiently delivered to the autop-
hagosomes. This preferentially affects organelle seques-
tration, in particular that of lipid droplets, which are seen
to be increased in Huntington’s disease, and mitochon-
dria, dysfunction in which have been widely reported in
Huntington’s disease [16].
Further evidence for a contribution of autophagy to
pathogenesis in HD comes from recent genetic studies,
which suggest that the V471A Atg7 polymorphism is
associated with earlier age of onset [17]. Whether orwww.sciencedirect.comnot this polymorphism has any effect on autophagic
activity has yet to be established.
Alzheimer’s disease
The (Ab) peptide plaques, which characterise AD, are
derived from proteolysis of amyloid precursor protein
(APP). Mutations in APP and presenilin (PS1), a protein
involved in APP to Ab proteolysis, cause rare autosomal
dominant forms of familial Alzheimer disease (FAD) [18–
20]. Sporadic AD, which is far more prevalent, presents
the same clinical and pathological characteristics, which
suggest that factors affecting the APP to Ab pathway play
a significant role in this form of the disease [21].
A prominent feature of AD is the accumulation of autop-
hagosomes, many containing amyloid-b peptide, in mas-
sive numbers within affected neurons [22], probably
reflecting defective autophagosome clearance [23].
Changes in the autophagic pathway have been linked
to AD through diverse mechanisms, however, it is not
clear if autophagosome formation is increased or
decreased. A decrease in formation is supported by the
reduction in levels of the autophagy protein Beclin-1
[24] or by inhibition of Beclin-1 activity by the HSV1
(Herpes Simplex Virus Type 1) viral protein ICP34.5
(Table 1) [25]. An increase in autophagosome formationCurrent Opinion in Cell Biology 2011, 23:190–197
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Table 1
Regulation of autophagy in proteinopathies
Disease Mutant protein Autophagy activity Mechanism
Alzheimer – Inhibition (AV formation) Beclin-1 targeting by HSV protein ICP34.5
– Inhibition (AV formation) Beclin-1 inhibition
PS1 Inhibition (AV maturation) Lysosome acidification (v-ATPase targeting)
– Induction (AV formation) ROS production
Parkinson a-Synuclein Inhibition (AV formation) Rab1 activity; Atg9 localisation
LRRK2 Inhibition (AV maturation) MVB formation; UPS impairment
PINK1 Inhibition (AV formation and mitophagy) PINK1/Beclin-1 interaction; mitochondria targeting
Parkin Inhibition (mitophagy) Mitochondria targeting
DJ-1 Induction (AV formation) ROS production; mTOR
Huntington Huntingtin Inhibition (selectivity) Cargo recognition
Lafora Laforin Inhibition (AV formation) mTOR activation
Malin Unknown
ALS Dynein Inhibition (AV maturation) Autophagosome transport to lysosome
Dynactin Unknown
ESCRT-III Inhibition (AV maturation) Autophagosome/lysosome fusion
Fig4 Inhibition Decreased PI(3,5)P2 levels
FTD3 ESCRT-III Inhibition (AV maturation) Autophagosome/lysosome fusionis supported by data suggesting that Ab is able to induce
autophagy via the generation of reactive oxygen species
[26].
Lysosome-related pathology, along with neuronal loss
and amyloid deposition, is greatly accentuated in FAD
due to mutations of PS1 [27]. PS1 appears to regulate
proteolysis during autophagy by targeting the v-ATPase
to lysosomes [28]. PS1 in the ER acts as a chaperone to
facilitate maturation and targeting of the v-ATPase V0a1
subunit to lysosomes, which is essential for acidification,
protease activation, and degradation of autophagic/lyso-
somal substrates and could account for the accumulation
of autophagosomes seen in AD.
Parkinson’s disease
Parkinson’s disease (PD) is characterised by the presence
of intraneuronal cytoplasmic inclusions known as Lewy
bodies, of which a-synuclein is a major constituent [29].
Several mutations have been identified in autosomal
recessive forms of PD that provide some insight into
the pathogenesis of this disease. Recent studies have
linked two such genes, PINK1 and Parkin with mito-
chondrial clearance and autophagy (Table 1). Parkin has
been demonstrated to be recruited to damaged mitochon-
dria and promote their clearance by autophagy [30] in a
manner that is dependent on the stabilisation of Pink1 on
the mitochondria [31,32,33,34]. This translocation is
disrupted by mutations in Pink1 or Parkin seen in familial
PD [31,32]. A direct interaction between Pink1 and
Beclin-1 has also been demonstrated recently, promoting
autophagosome formation [35], further strengthening the
link between autophagy and PD.
Mitochondrial dysfunction has also been linked to
mutations of DJ-1 (PARK7), another autosomal recessive
PD gene [36]. Its loss, which can be rescued by theCurrent Opinion in Cell Biology 2011, 23:190–197expression of Pink1 and Parkin, leads to increased
susceptibility of neurons to oxidative stress and death.
Interestingly, DJ1-deficiency leads to increased autopha-
gic activity [36], probably with the aim of clearing dys-
functional mitochondria, by a mechanism that remains to
be established, but could involve ROS production,
mTOR signalling or direct interaction with Pink1/Parkin
pathway [36].
Autosomal dominant mutations in leucine-rich repeat
kinase 2 (LRRK2) are the most common genetic cause
of PD [37,38]. LRRK2 loss causes phenotypes that may
be due to impairment of the autophagy-lysosomal path-
way, like the accumulation of a-synuclein and apoptotic
cell death in aged mice [39]. The effect of LRRK2 on
autophagy still remains to be elucidated but might
involve the formation of multivesicular bodies (MVB)
or the inhibition of the UPS system following the
accumulation of a-synuclein (Table 1).
Mutations in the a-synuclein gene, including point
mutations and multiplications of the entire locus, have
been shown to cause autosomal dominant forms of PD,
although the mechanism still remains obscure. In yeast,
overexpression of a-synuclein perturbs the secretory
pathway by inhibiting Rab1 activity [40]. We recently
found that a-synuclein overexpression causes autophagy
inhibition by inhibiting Rab1a [41].
Dementia and amyotrophic lateral sclerosis
A group of neurodegenerative proteinopathies, such as
motor neuron diseases (MND), are associated with
defects in autophagosome trafficking. Disruption of retro-
grade axonal transport of cargo by overexpression or
depletion of dynein complex components in transgenic
mice results in the progressive degeneration of motor
neurons and the formation of inclusions, mimicking thewww.sciencedirect.com
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activity is crucial for microtubule-based delivery of autop-
hagosomes to lysosomes, mutations in the dyneinmachin-
ery impair autophagosome clearance. Indeed, an increase
in autophagosome number and LC3-II levels can be
observed in mice with dynein mutations [45,46]. Further
research will be needed to clarify the relative importance
of autophagy dysfunction in MND, particularly in forms
not due to primary mutations of the dynein machinery,
but where axonal transport deficiencies have been
reported.
Another group of diseases that manifest impaired autop-
hagic flux are due to mutations in the ESCRT complex
machinery, which has been implicated in neurodegen-
erative disorders, such as frontotemporal dementia linked
to chromosome 3 (FTD3) [47] and amyotrophic lateral
sclerosis (ALS) [48,49]. Expression of a deletion mutant
of CHMP2B, a subunit of the ESCRT-III complex, in
cell and flymodels, increased LC3-II levels and caused an
accumulation of autophagosomes [50]. Experimental
characterisation of CHMP2B indicates that the proper
dissociation of the ESCRT-III complex is crucial to both
autophagosome maturation and proper fusion of autop-
hagosomes with lysosomes [51].
Further evidence suggesting a perturbation of autophagy
may contribute to pathogenesis of ALS and other associ-
ated disorders comes from studies of the lipid phosphatase
Fig4. Mutations in this gene are responsible for Charcot-
Marie-Tooth disease type 4 and a variant has also been
described in ALS patients [52]. A decrease in PI(3,5)P2
levels mice lacking Fig4 has been reported, and this is
associated with alterations in autophagic markers consist-
ent with a decrease in autophagy in these animals [53].
Lafora disease
Lafora disease (LD) is an autosomal recessive myoclonus
epilepsy. Its pathological hallmark is the accumulation of
polyglucosan inclusions, called Lafora bodies, in the cyto-
plasm of cells in many organs. The majority of mutations
causing LD occur in two genes: EPM2A, which encodes
laforin, and EPM2B, which codes for malin [54]. It has
recently been demonstrated that a deficiency in autophagy
may contribute to the accumulation of Lafora bodies [55].
Data obtained inpatient cells, laforinknockoutmice and in
cell culture systems showed that laforin is a positive
regulator of autophagy (Table 1). Loss of laforin resulted
in an increase in the activity of the negative regulator of
autophagy, mTOR. The exact mechanism for the laforin
effect on autophagy is still elusive, as specific laforin
substrates relevant to autophagy have yet to be identified.
Protection by autophagy induction in protein
misfolding disorders
While progress has been made in understanding the
molecular pathology of protein misfolding disorders,www.sciencedirect.comexactly how these proteins cause cellular toxicity still
remains to be elucidated. However, extensive data
suggest that toxicity is mediated primarily via gain-of-
function mechanisms (Figure 1). Disease severity appears
to correlate with the level of expression of the mutant
protein, while loss-of-function mutants often show phe-
notypes distinct from the disease. Whether it is the
aggregated protein, the soluble protein, or an intermedi-
ate oligomeric form that confers this toxic gain-of-func-
tion is a matter of controversy. However, the large
aggregates visible by light microscopy may not be the
most toxic species [56]. Regardless of the exact toxic
species, the fact these diseases result from a toxic gain-
of-function means that the efficiency of the removal of
the mutant proteins from the cell is likely to be an
important factor in their toxicity.
In general, intracytoplasmic aggregate-prone proteins are
good autophagy substrates [57,58], although there are
some exceptions to this [59]. Clearance by autophagy
has been demonstrated for both wild-type and mutant
forms of tau [58], mutant forms of a-synuclein that cause
familial Parkinson’s disease [60] and a range of polyglu-
tamine-expanded proteins [14,57,58,61]. Interestingly,
the non-aggregate-prone species of many of these
proteins (e.g. huntingtin and a-synuclein) show a much
lower dependency on autophagy for their clearance,
compared to their mutant counterparts [60,62–64]. This
may have additional benefits in certain neurodegenera-
tive diseases, allowing preferential clearance of the
mutant/aggregate-prone protein, without affecting wild-
type protein levels.
The importance of autophagy in aggregate-prone protein
clearance is probably increased due to the proteasome
being unable to degrade oligomeric species, as they
cannot be unfolded to enter the narrow barrel of the
proteasome [65]. Additionally, in the case of polygluta-
mine proteins, the proteasome may be unable to cleave
within the polyglutamine tract [65,66]. By contrast, autop-
hagosomes are able to engulf oligomeric species. This
does not mean that autophagy clears purely aggregated
species, as its upregulation results in a decrease in the
levels of both soluble and aggregated protein forms [60].
Equally, it is not known if autophagy can clear large
aggregates directly or if a decrease in aggregates is seen
due to a decrease in the soluble levels of the protein
[67,68], although aggregates visible by light microscopy
are not membrane-bound, suggesting that earlier and
smaller oligomeric structures are the autophagy sub-
strates.
Therapeutic implications for upregulation of
autophagy
Evidence for the importance of autophagy in the
degradation of mutant, misfolded proteins has wide thera-
peutic implications in the treatment of proteinopathies.Current Opinion in Cell Biology 2011, 23:190–197
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hagy, using the mTOR inhibitor rapamycin or its
water-soluble ester CCI-779, reduced levels of soluble
and aggregated mutant huntingtin and was protective in
cell, Drosophila and mouse models of Huntington’s dis-
ease [14]. Further to this it has been demonstrated that
genetic inhibition of mTOR, by overexpression of TSC1
and TSC2, conferred neuroprotective effects in a Droso-
phila model of Huntington’s disease [69]. Indeed, the
therapeutic scope for upregulation of autophagy by
mTOR inhibitors extends beyond Huntington’s disease,
as CCI-779 treatment also demonstrated protective
effects in a mouse model of spinocerebellar type 3 [70].
As the most common neurodegenerative disease, possible
treatments for AD are of great interest, and there is now
evidence that a rapamycin treatment may be beneficial.
Ab levels were decreased and cognitive defects were
prevented by rapamycin treatment in two different AD
mouse models [71,72]. Further evidence for a potential
protective role of autophagy upregulation in AD comes
from genetic studies. Overexpression of Beclin-1, an
autophagy regulating gene, in AD mice models reduced
intracellular accumulation of Ab and extracellular depo-
sition of Ab plaques [24]. This strategy of autophagy
upregulation has also proved beneficial in a mouse model
of Parkinson’s disease overexpressing a-synuclein [73].
While mTOR inhibitors show some potential as thera-
peutic agents, mTOR has multiple roles in cellular
homeostasis, and thus mTOR inhibitors are likely to have
side-effects due to modulations in processes other than
autophagy. It has therefore become a priority to identify
other drugs that induce autophagy via mTOR-indepen-
dent mechanisms. Screening of United States Food and
Drug Administration-approved drugs with this aim in
mind, identified a number of drugs that were able to
upregulate autophagy and protect against toxicity in cell,
Drosophila and zebrafish models of Huntington’s disease
[74]. One of these drugs, rilmenidine, a centrally acting
anti-hypertensive, has subsequently been shown to be
protective in a mouse model of Huntington’s disease
[75].
Lithium induces autophagy by lowering intracellular
inositol or inositol 1,4,5-trisphosphate (IP3) levels in an
mTOR-independent manner [76], and it has been shown
to delay disease progression in a mouse model of ALS
overexpressing a mutant form of SOD1 and also in a small
trial with ALS patients [77]. Cellular studies have pre-
viously demonstrated the requirement of autophagy for
the clearance of SOD1 [78], and more recently for TDP-
43, another aggregate-prone protein, mutations in which
cause ALS [79,80] suggesting that there may be thera-
peutic potential for the upregulation of autophagy in
ALS. Further support for this comes from evidence that
XBP-1 deficiency protects against neurodegeneration inCurrent Opinion in Cell Biology 2011, 23:190–197mice overexpressing mutant SOD1 [81]. XBP-1 is a
transcription factor required for induction of the unfolded
protein response (UPR), and it was therefore predicted
that its loss would increase the toxicity of mutant SOD in
a mouse model. However, deficiency of XBP-1 markedly
attenuated development of disease signs, as it resulted in
an increase in autophagy and decreased levels of SOD1
aggregation [81].
Autophagy can also be upregulated in an mTOR-inde-
pendent manner by the disaccharide trehalose [64].
Treatment of a mouse model of tauopathy with parkin-
sonism, in which mutant tau is overexpressed along with a
parkin deletion, resulted in a decrease in the levels of
phosphorylated tau and protection against loss of dopa-
minergic neurons [82]. Trehalose has previously been
shown to have neuroprotective effects, which were attrib-
uted to its activity as a chemical chaperone (see [83] for
review). However, in this mouse model, an upregulation
of autophagy was seen, confirming the potential for dual
mechanisms of protection by trehalose.
Future perspectives
For many diseases, the upregulation of autophagy is a
promising therapeutic target. Combining knowledge of
the potential mechanisms of autophagy compromise in
neurodegenerative proteinopathies with knowledge of
the range of signalling pathways and drugs available to
control autophagy may make the development of thera-
peutics based on this process possible.
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